Lucan · Conditions

Terminal symptom control

Australian guidance: eTG Palliative Care + CareSearch + RACGP

1. Definition and epidemiology

Terminal symptom control refers to the active pharmacological and non-pharmacological management of distressing symptoms in patients during the final days to weeks of life, when cure or disease modification is no longer the goal. In Australia, approximately 160,000 deaths occur annually, with around 70% of these being expected and therefore amenable to palliative planning. The RACGP Silver Book identifies palliative and end-of-life care as a foundational chapter applicable across all aged care clinical encounters, reflecting how common this work is for GPs managing residential aged care facility residents.

2. Pathophysiology

Terminal symptoms arise from a convergence of disease-specific pathology, systemic physiological decline, and treatment effects. Pain in the dying patient results from tissue invasion by tumour, visceral distension, nerve compression, ischaemia, or inflammation. Dyspnoea reflects reduced respiratory muscle reserve, pulmonary oedema, pleural effusion, anaemia, or airway obstruction; the subjective sensation is amplified by anxiety and reduced cortical inhibition as consciousness fluctuates. Nausea is driven by stimulation of the chemoreceptor trigger zone via opioid metabolites, uraemia, or hypercalcaemia, and by gastric stasis from autonomic neuropathy or bowel obstruction. Terminal secretions (the death rattle) result from loss of the swallowing reflex with pooling of oropharyngeal and bronchial secretions. Delirium in the dying patient reflects multifactorial cerebral dysfunction: opioid accumulation, renal failure with uraemic encephalopathy, hypoxia, hypercalcaemia, infection, and brain metastases all contribute. Agitation at end of life may represent uncontrolled pain, urinary retention, constipation, unrecognised delirium, or existential distress rather than a primary psychiatric state.

3. Clinical presentation and diagnostic criteria

The diagnosis of the terminal phase (last 48 to 72 hours) is clinical. Key indicators include profound fatigue and bed-bound state, reduced oral intake and swallowing difficulty, mottling and peripheral cyanosis, Cheyne-Stokes or Kussmaul breathing patterns, and reduced conscious state. The Liverpool Care Pathway (no longer used in AU) has been replaced by individualised goals-of-care frameworks. Common presenting symptoms requiring active management include pain (reported in 60 to 90% of dying cancer patients), dyspnoea (up to 70%), nausea and vomiting, terminal secretions, delirium and agitation, and existential or refractory psychological distress. Clinicians should assess symptom burden using a validated tool such as the Edmonton Symptom Assessment System (ESAS) and document goals of care in an advance care plan where possible.

4. Investigations and AU-specific cutoffs

Investigations are generally restricted to those that will directly change symptom management. Blood glucose (fingerprick) may guide insulin decisions if comfort remains a goal. Serum calcium (corrected) is checked if hypercalcaemia is suspected as a reversible cause of delirium or nausea; corrected calcium above 2.6 mmol/L warrants consideration of a single dose of intravenous pamidronate or subcutaneous zoledronic acid if the patient is still sufficiently well to benefit. Urine dipstick may confirm symptomatic urinary tract infection treatable with a short antibiotic course if this aligns with goals. Imaging and biochemistry panels should not be ordered routinely in the terminal phase; each test should be justified against whether its result would change management aimed at comfort. Syringe driver setup does not require laboratory confirmation before commencement when clinical need is clear.

5. Management

Management follows an AU guideline-anchored comfort-focused framework. A syringe driver (continuous subcutaneous infusion) is the preferred route once oral intake is no longer possible; this is standard practice across AU palliative care services and recommended by eTG Palliative Care. Anticipatory prescribing of as-needed (PRN) subcutaneous medications should be written before the patient enters the terminal phase to avoid delays at the time of need. Typical anticipatory medications include a subcutaneous opioid for pain and dyspnoea, a subcutaneous antiemetic, a subcutaneous anxiolytic or sedative, and a subcutaneous anticholinergic for terminal secretions. Goals-of-care documentation must be completed or reviewed, and family should be supported with clear and compassionate communication about expected disease trajectory. Non-pharmacological measures include mouth care with moistened swabs, repositioning to reduce pressure injury, soft lighting, minimising unnecessary monitoring, and family presence.

6. Pharmacology and AU PBS notes

Pain and dyspnoea: First-line is subcutaneous morphine. In opioid-naive adults, a typical starting dose is morphine 2.5 to 5 mg subcutaneously every four hours, with 2.5 mg PRN hourly. Oxycodone subcutaneous is an alternative. Hydromorphone is used when morphine is poorly tolerated (myoclonus, hallucinations from accumulation of metabolites in renal impairment). PBS: morphine and oxycodone are PBS listed for palliative care; hydromorphone requires authority (Section 100 Palliative Care Program in some states).

Nausea: Metoclopramide 10 mg subcutaneous four-hourly or as a syringe driver infusion for prokinetic-responsive nausea. Haloperidol 0.5 to 2 mg subcutaneous twice daily or via syringe driver for chemoreceptor-trigger-zone-mediated nausea (opioid-induced, uraemic). Ondansetron is less commonly used in the terminal phase but available if haloperidol is unsuitable. Levomepromazine 6.25 to 12.5 mg subcutaneous is a broad-spectrum antiemetic and anxiolytic used when multiple symptom control is needed via a single agent.

Agitation and delirium: Midazolam 2.5 to 5 mg subcutaneous PRN, or via syringe driver, is first-line for terminal agitation and refractory dyspnoea. Haloperidol 0.5 to 2 mg subcutaneous is first-line for hyperactive delirium if sedation is not the goal. Clonazepam subcutaneous is used when seizures co-exist with agitation.

Terminal secretions: Hyoscine butylbromide (Buscopan) 20 mg subcutaneous PRN or syringe driver is first-line in AU. Glycopyrrolate 0.2 mg subcutaneous is an alternative with less CNS penetration. Hyoscine hydrobromide (Kwells) causes more sedation and is less preferred. Suction is generally not recommended as it causes distress without clear benefit.

Palliative sedation: For refractory symptoms where all other measures have failed, proportionate palliative sedation using midazolam infusion (starting 10 to 30 mg per 24 hours) is ethically and legally sanctioned in all AU states. This is distinct from voluntary assisted dying.

7. Complications and monitoring

Key risks during syringe driver use include precipitation of drugs in the driver (avoid mixing midazolam with dexamethasone without compatibility check), site reactions requiring rotation every 72 hours, and inadvertent under-dosing if breakthrough requirements are not reviewed and the background infusion rate adjusted. Respiratory depression from opioids in the dying patient is less common than feared; the priority is symptom relief. Families may distress at observing the Cheyne-Stokes breathing pattern; clinician explanation reduces carer anxiety. Monitoring in the terminal phase is symptom-focused rather than vital-sign-focused: reassess pain, dyspnoea, agitation, and secretions at each review (typically four-hourly by nursing staff). Documentation of PRN use informs syringe driver dose adjustments. After death, the GP is responsible for issuing the death certificate; if death was unexpected or the cause uncertain, notification to the coroner is mandatory under the AU Coroners Act in the relevant state.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.